Cor Vasa 2011, 53(4-5):220-229 | DOI: 10.33678/cor.2011.050

The prevalence of major cardiovascular risk factors in the Czech population in 2006-2009. The Czech post-MONICA study

Renata Cífková1,2,3,*, Jan Bruthans3, Věra Adámková3, Marie Jozífová1,3, Markéta Galovcová3, Peter Wohlfahrt3, Alena Krajčoviechová1,3, Zdena Petržílková3, Věra Lánská4, Rudolf Poledne5, Petr Stávek5
1 Centrum kardiovaskulární prevence, 1. lékařská fakulta Univerzity Karlovy a Fakultní Thomayerova nemocnice s poliklinikou
2 II. interní klinika kardiologie a angiologie, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice
3 Pracoviště preventivní kardiologie
4 Oddělení lékařské statistiky
5 Laboratoř pro výzkum aterosklerózy, Institut klinické a experimentální medicíny, Praha, Česká republika

Cardiovascular disease (CVD) is the main cause of death in the Czech Republic. The decline in CVD mortality observed in our country since 1985 may be due to a decrease in its incidence or case fatality. Case fatality is mostly related to the standard of health care whereas the incidence of CVD is associated with the risk profile of the population. The aim of this study was to determine the prevalence of major CVD risk factors in a representative Czech population sample.

Methods: A 1% population sample aged 25-64 years was randomly selected from nine districts of the Czech Republic. The examination consisted of completing a standard questionnaire, obtaining major anthropometric data, repeated blood pressure measurements, and blood sampling.

Results: A total of 3612 individuals (1737 males, mean age 47.8 ± 11.48 years, and 1875 females, mean age 46.5 ± 11.20 years) were screened in 2006-2009 (response rate, 62.2%). Mean BMI in our population was 28.5 ± 4.7 kg/m2 in males and 27.1 ± 6.0 kg/m2 in females (p < 0,001). Obesity was found in 32.4% of males and 28.3% females. Among the males, 31.9% reported to be regular smokers whereas smoking was found in 23.3% females (p < 0.001). There was a high prevalence of hypertension (47.8% of males and 36.6% of females; p < 0.001); 71.9% of hypertensives were aware of their disease, 60.3% were drug treated, and 30.9 % were controlled (blood pressure < 140/90 mmHg). Females, while having a lower prevalence of hypertension, are more often aware of their disease, are more frequently treated by antihypertensive drugs, and are more often controlled. The mean total cholesterol in our population was identical in males and females (5.29 ± 1.10 mmol/l and 5.29 ± 1.04 mmol/l, respectively). Lipid-lowering drugs were used by 12.7% of males and 8.5% of females (p < 0.001). Diabetes was found in 9.4% of males and 4.7% of females (p < 0.001). The prevalence of all major risk factors increased significantly with age in both sexes (p for trend < 0.001).

Conclusion: A high prevalence of major cardiovascular risk factors was found in a representative Czech population sample, which is the cause of continuing high cardiovascular mortality in the Czech Republic.

Keywords: Cardiovascular diseases; Population random sample; BMI; Smoking; Blood pressure; Hypertension; Total cholesterol

Published: April 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cífková R, Bruthans J, Adámková V, Jozífová M, Galovcová M, Wohlfahrt P, et al.. The prevalence of major cardiovascular risk factors in the Czech population in 2006-2009. The Czech post-MONICA study. Cor Vasa. 2011;53(4-5):220-229. doi: 10.33678/cor.2011.050.
Download citation

References

  1. Zemřelí 2009. ÚZIS, ČR, 2010.
  2. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997;18:1231-1248. Go to original source...
  3. Müller-Nordhorn J, Binting S, et al. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J 2008;29:1316-1326. Go to original source... Go to PubMed...
  4. European cardiovascular disease statistics 2008. 3rd ed. Brussels: European Heart Network, 2008.
  5. WHO MONICA Project Principal Investigators: The World Health Organization MONICA project (Monitoring trends and determinants in cardiovascular disease): A major international collaboration. J Clin Epidemiol 1988;41:105-114. Go to original source...
  6. Tunstall-Pedoe H, Kuulasmaa K, Mähönen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547-1557. Go to original source... Go to PubMed...
  7. Kannel WB, McGee DL, Gordon T. A general cardiovascular risk profile: The Framingham Study. Am J Cardiol 1976;74:46-51. Go to original source... Go to PubMed...
  8. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-362. Go to original source...
  9. Pyörala K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:130-131. Go to original source... Go to PubMed...
  10. Wood D, De Backer G, Faergeman O, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-1503. Go to original source... Go to PubMed...
  11. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 02-5215. Circulation 2002;106:3143-3420. Go to original source...
  12. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-1610. Go to original source... Go to PubMed...
  13. Yusuf S, Hawken S, Ôunpuu S, et al; and INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 2004;364:937-952. Go to original source... Go to PubMed...
  14. Graham I, Atar D, Borch-Jonsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardio Prev Rehab 2007;14(Supp 2):S1-S88. Go to original source... Go to PubMed...
  15. Cífková R, Škodová Z, Bruthans J, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010;211:676-681. Go to original source... Go to PubMed...
  16. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. for the WHO MONICA Project. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000;355:675-687. Go to original source...
  17. Berghöfer A, Pischon T, Reinhold T, et al. Obesity prevalence from a European perspective. A systematic review. BMC Public Health 2008;8:200. Go to original source... Go to PubMed...
  18. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241. Go to original source... Go to PubMed...
  19. Seidell JC. Time trends in obesity: An epidemiological perspective. Horm Metab Res 1997;29:155-158. Go to original source... Go to PubMed...
  20. Seidell JC. Obesity in Europe: scaling an epidemic. Int J Obes 1995;19:S1-S4.
  21. Flegal KM, Caroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes 1998;22:39-47. Go to original source... Go to PubMed...
  22. Williamson DF, Madans J, Anda RF, et al. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991;324:739-745. Go to original source... Go to PubMed...
  23. Boyle CA, Dobson AJ, Egger C, Magnus P. Can the increasing weight of Australians be explained by the decreasing prevalence of cigarette smoking? Int J Obes 1994;18:55-60.
  24. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity impact on cardiovascular disease. Circulation 1998;98:1472-1476. Go to original source...
  25. Eckel RH. Obesity and heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997;96:3248-3250. Go to original source...
  26. Dengel DR, Galeckim AT, Hagberg JM, Pratley RE. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. Am J Hypertens 1998;11: 1405-1412. Go to original source...
  27. Pleis JR, Lucus JW, Ward BW. Summary health statistics for U.S. adults: National Health Interview Survey, 2008. Vital Health Stat 10 2009;(242):1-157.
  28. Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998;279:119-124. Go to original source...
  29. Lopez AD, Collishaw NE, Piha T. A descriptive model of the cigarette epidemic in developed countries. Tobacco Control 1994;3:242-247. Go to original source...
  30. Molarius A, Parson RW, Dobson AJ, et al. Trends in cigarette smoking in 36 population from the early 1980s to the mid-1990s: Findings from the WHO MONICA project. Am J Public Health 2001;91:206-212. Go to original source...
  31. Cífková R, Škodová Z, Bruthans J, et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010;28:2196-2203. Go to original source... Go to PubMed...
  32. Elliott P, Stamler J, Nichols R, et al. for the Intersalt Cooperative Research Group et al. Intersalt revisited: further analyses of 24-hour sodium excretion and blood pressure within and across populations. BMJ 1996;312:1249-1253. Go to original source...
  33. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? Analysis of data from trials of salt reduction. BMJ 1991;302:819-824. Go to original source... Go to PubMed...
  34. Cutler JA, Follmann D, Alender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997;65:643S-651S. Go to original source... Go to PubMed...
  35. Midgley JP, Matthew AG, Greenwood CMT, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996;275:1590-1597. Go to original source... Go to PubMed...
  36. Sacks FM, Svetkey LP, Vollmer WM, et al; for the DASH-sodium collaborative research group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10. Go to original source... Go to PubMed...
  37. Puddey IB, Beilin LJ, Rakic V. Alcohol, hypertension and the cardiovascular system: a critical appraisal. Addiction Biol 1997;2:159-170. Go to original source... Go to PubMed...
  38. Food consumption data released the Czech Statistical Office at: http://www.czso.cz: table 03.02: Food consumption and non-alcoholic beverages in 1989-2007.
  39. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-827. Go to original source... Go to PubMed...
  40. Erdine S, Aran SN. Current status of hypertension control around the world. Clin Exp Hypertens 2004;26:731-738. Go to original source... Go to PubMed...
  41. Marques-Vidal P, Tuomilehto J. Hypertension, awareness, treatment and control in the community: is the rule of halves still valid. J Hum Hypertens 1997;11:213-220. Go to original source... Go to PubMed...
  42. Joffres MR, Ghadirian P, Fodor JG, et al. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097-1102. Go to original source...
  43. Leenen FH, Dumais J, McInnis NH, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008;178: 1441-1449. Go to original source... Go to PubMed...
  44. Hansson L, Zancheti A, Carruthers SG, et al; on behalf of the HOT Study Group. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998:351: 1755-1762. Go to original source...
  45. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300. Go to original source... Go to PubMed...
  46. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002;20:1461-1464. Go to original source...
  47. Vartiainen E, Puska P, Pekkanen J, et al. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994;309:23-27. Go to original source...
  48. Puska P. The North Karelia Project: From community intervention to national activity in lowering cholesterol levels and CHD risk. Eur Heart J 1999;20:S9-S13.
  49. Bruthans J, Cífková R, Lánská V, et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007 (odesláno do tisku).
  50. The DECODE study group on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and Cardiovascular Mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001:161; 397-404.
  51. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197. Go to original source...
  52. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Organization, 1999.
  53. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO consultation/IDF Consultation. Geneva, World Health Organization, 2006.
  54. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524. Go to original source...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.